Skip to content

Antigen

Antigen is a Y Combinator-backed continuous offensive security platform that runs nightly automated attack simulations against an organization's cloud and application attack surface, backed by monthly human red-team assessments, delivering findings with reproduction steps directly into engineering ticketing systems.

Visit Website ↗ + Add to Compare
47/100Emerging / Unranked

Overview

Antigen combines nightly automated offensive security testing with monthly human red-team assessments to continuously map and exploit an organization’s attack surface, rather than relying on annual point-in-time penetration tests. Findings come with traces and reproduction steps delivered directly into GitHub, Linear, or Antigen’s own platform, aimed at making offensive security output actionable for engineering teams rather than sitting in a PDF report.

The company went through Y Combinator’s Fall 2025 batch, is based in the San Francisco Bay Area, and is backed by Lightspeed Venture Partners, DST Global, and Susa Ventures.

Innovation Matrix Assessment

Innovation Velocity 5/10

As a company founded in 2025, Antigen has already built a nightly automated testing product with GitHub/Linear ticketing integration, indicating a fast initial build pace typical of well-backed YC companies.

Operational Value 6/10

Delivering findings as actionable tickets with reproduction steps directly into engineering workflows, rather than static PDF reports, reduces the translation gap between offensive security findings and actual remediation.

Market Momentum 4/10

Backing from Lightspeed Venture Partners, DST Global, and Susa Ventures is a notable early signal for such a young company, though no customer count or funding amount is disclosed.

Category Disruption 5/10

Shifting from annual point-in-time penetration testing to continuous nightly automated testing plus monthly human validation is a meaningful operating-model change versus traditional pentest firms.

Real-World Efficacy 3/10

As an extremely early-stage company, no independent efficacy data, customer references, or third-party benchmark was found; effectiveness is currently unverified.

Enduring Relevance 5/10

Continuous, always-on offensive security testing addresses a well-recognized limitation of annual pentesting, supporting durable relevance for the underlying model regardless of this specific vendor's outcome.

Why CISOs Should Care

Annual penetration tests leave months-long gaps between assessments during which new vulnerabilities go undetected; continuous automated testing backed by human validation gives CISOs a more current picture of actual exploitability in their cloud attack surface.

What Makes It Different

Combining nightly automated testing with monthly human red-team validation, and delivering results as actionable engineering tickets rather than static reports, differentiates Antigen from both point-in-time pentest firms and pure automated scanners.

The Matrix Verdict

47/100 — EMERGING / UNRANKED

A very early-stage but notably well-backed continuous offensive security entrant (Lightspeed, DST Global); scores are appropriately conservative given its very recent founding and lack of disclosed customer or efficacy data.

Editorial Note: Claims vs. Verified Findings

YC batch, headquarters, and named investors are independently confirmed via Antigen's Y Combinator company page; specific funding amount, customer count, and vulnerability-detection accuracy are not disclosed.

Sources